Haemophagocytic syndrome - A life-threatening complication of renal transplantation

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2623-2627

  Ponticelli, Claudio ^a   Alberighi, Ornella Della Casa ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Haemophagocytic syndrome; Macrophage activation; Transplant complications

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; PREDNISONE; RAPAMYCIN;

CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; EDITORIAL; HEMOPHAGOCYTIC SYNDROME; HUMAN; KIDNEY TRANSPLANTATION; LABORATORY TEST; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL;

BONE MARROW EXAMINATION; HUMANS; INFECTION; KIDNEY TRANSPLANTATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PROGNOSIS;

EID: 69249159417     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp282     Document Type: Editorial

References (66)

1. Janka G, Zur Stadt U. Familial and acquired hemophagocytic lymphohisticytosis. Hematology 2005; 32: 82-88
2. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002; 14: 548-552
3. Henter JI, Tondini C, Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol 2004; 50: 157-174
4. Janka G, Imashuku S, Elinder G et al. Infection-and malignancyassociated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998; 12: 435-444
5. Stepp SE, Dufourq-LagelouseR, LeDeist F et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-1959
6. Feldmann J, Callebaut I, Raposo G et al. Munc 13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL-3). Cell 2003; 115: 461-473
7. Horne A, Ramme KG, Rudd E et al. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol 2008; 143: 75-83
8. Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders. Curr Opin Allergy Clin Immunol 2006; 6: 410-415
9. Risdall RJ, Brunning RD, Hernandez JI et al. Bacteria-associated hemophagocytic syndrome. Cancer 1984; 54: 2968-2972
10. Dhote R, Simon J, Papo T et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003; 49: 633-639
11. Ravelli A, Magni-Manzoni S, Pistorio A et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598-604
12. Grom AA, Villanueva J, Lee S et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292-6. 20
13. Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 1989; 73: 2128-2132
14. Henter JI, Elinder G, Soder O et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78: 2918-2922
15. Osugi Y, Hara J, Tagawa S et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 1997; 89: 4100-4103
16. Jordan MB, Hildeman D, Kappler J et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+T cells and interferon gamma are essential for the disorder. Blood 2004; 104: 735-743
17. Nakanishi K, Yoshimoto T, Tsutsui H et al. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423-474
18. Mazodier K, Marin V, Novick D et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005; 106: 3483-3916
19. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007; 27: 98-114
20. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103: 11-24
21. Pelegrin P. Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7) receptor and Pannexin-1. Drug News Perspect 2008; 21: 424-433
22. Chen L, Brosnan CF. Regulation of immune response by P2×7 receptor. Crit Rev Immunol 2006; 26: 499-513
23. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med 2006; 38: 20-31
24. Villanueva J, Lee S, Giannini EH et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7: R30-R37
25. Schmid JM, Junge SA, Hossle JP et al. Transient hemophagocytosis with deficient cellular cytotoxicity, monoclonal immunoglobulin M gammopathy, increased T-cell numbers, and hypomorphic NEMO mutation. Pediatrics 2006; 117: 1049-1056
26. Risdall RJ, McKenna RW, Nesbit ME et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993-1002
27. Broeckaert-Van Orschoven A, Michielsen P, Vandepitte J. Fatal leishmaniasis in a renal transplant patient. Lancet 1979; 2: 740-741
28. Reiner A, Spivak J. Hemophagocytic histiocytosis: a report of 23 new patients and a review of the literature. Medicine 1988; 67: 369-388
29. Kaplan MA, Jacobson JO, Ferry JA et al. T-cell lymphoma of the vulva in a renal allograft recipient with associated hemophagocytosis. Am J Surg Pathol 1993; 17: 842-849
30. Boehler A, Schaffner A, Salomon F et al. CMV disease of late onset following renal transplantation: a potentially fatal entity. Scand J Infect Dis 1994; 26: 369-373
31. Drut R, Drut RM. EBV-associated Kaposi's sarcoma in a pediatric renal transplant recipient. Pediatr Pathol 1994; 14: 863-872
32. Gupta P, Hurley RW, Helseth PH et al. Pancytopenia due to hemophagocytic syndrome as the presentingmanifestation of babesiosis. Am J Hematol 1995; 50: 60-62
33. Rostaing L, Fillola G, Baron E et al. Course of hemophagocytic syndrome in renal transplant patients. Transplantation 1995; 60: 506-509
34. Calonge VM, Glotz D, Bouscary D et al. Hemophagocytic histiocytosis in renal transplant recipients under cyclosporine therapy: report of two cases. Clin Transplant 1995; 9: 88-91
35. Slovut DP, Benedetti E, Matas AJ. Babesiosis and hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation 1996; 62: 537-539
36. Kursat S, Cagirgan S, Ok E et al. Haemophagocytic-histiocytic syndrome in renal transplantation. Nephrol Dial Transplant 1997; 12: 1058-1060
37. Dargent JL, Vermylen P, Abramowicz D et al. Disseminated angiosarcoma presenting as a hemophagocytic syndrome in a renal allograft recipient. Transpl Int 1997; 10: 61-64
38. Peeters P, Sennesael J, De Raeve H et al. Hemophagocytic syndrome and T-cell lymphoma after kidney transplantation: a case report. Transpl Int 1997; 10: 471-474
39. Rossi C, Delforge ML, Jacobs F et al. Fatal primary infection due to HHV6 variant in a renal transplant recipient. Transplantation 2001; 71: 288-292
40. Luppi M, Barozzi P, Rasini V et al. Severe pancytopenia and hemophagocytosis after HHV8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 2002; 74: 131-132
41. Karras A, Thervet E, Legendre C. Groupe Cooperatif de transplantation díle de France. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation 2004; 77: 238-243
42. Gurkan A, Yakupoglu U, Yavuz A et al. Hemophagocytic syndrome in kidney transplant recipients: report of four cases from a single center. Acta Haematol 2006; 116: 108-113
43. Hot A, Madoux MH, Viard JP et al. Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins. Am J Hematol 2008; 83: 159-162
44. Bossini N, Sandrini S, Setti G et al. Successful treatment with liposomal doxorubicin and foscarnet in a patient with widespread Kaposi's sarcoma and human herpes virus 8-related, serious hemophagocytic syndrome, after renal transplantation. G Ital Nefrol 2005; 22: 281-286
45. Esposito L, Hirsch H, BasseGet al. BKvirus-related hemophagocytic syndrome in a renal transplant patient (letter). Transplantation 2007; 83: 365
46. Asci G, Toz H, Ozkahya M et al. High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome. J Nephrol 2006; 19: 322-326
47. Segall L, Moal MC, Doucet L et al. Toxoplasmosis-associated hemophagocytic syndrome in renal transplantation. Transpl Int 2006; 19: 78-80
48. González-Posada JM, Hernández D, Martin A et al. Hemophagocytic lymphohistiocytosis in a pancreas-kidney transplant recipient: response to dexamethasone and cyclosporine. Clin Nephrol 2008; 70: 82-86
49. Ardalan MR, Shoja MM, Tubbs RS et al. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus B19 infection. Am J Transplant 2008; 8: 1340-1344
50. Yoshiaki K, Jiro M, Yoshida M et al. Hemophagocytic syndrome in an ABO-incompatible living renal transplant recipient with acute rejection during the chronic phase. Nishinihon J Urol 1999; 61: 341-343
51. Emmenegger U, Schaer DJ, Larroche C et al. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 2005; 135: 299-314
52. Woolley I, Jones P, Spelman D et al. Cost-effectiveness of a postsplenectomy registry for prevention of sepsis in the asplenic. Aust N Z J Public Health 2006; 30: 558-561
53. de Saint Basile G, Fischer A. The role of cytotoxicity in lymphocyte homeostasis. Curr Opin Immunol 2001; 13: 549-554
54. Turgeon AF, HuttonB, FergussonDAet al.Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007; 146: 193-203
55. Bruhns P, Samuelsson A, Pollard JWet al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIg protection in antibody-induced autoimmune disease. Immunity 2003; 18: 573-581
56. Ichiyama T, Ueno Y, Hasegawa M et al. Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 428-433
57. Kaito K, Otsubo H, Takei Y et al. Immunosuppressive therapy with antithymocyte globulin and cyclosporine for prolongedmarrowfailure after hemophagocytic syndrome. Ann Hematol 2003; 82: 699-701
58. Pradalier A, Teillet F, Molitor JL et al. Macrophage activation syndrome, hemophagocytic syndrome. Pathol Biol (Paris) 2004; 52: 407-414
59. Wong PK, Cuello C, Bertouch JV et al. Effects of pulse methylprednisolone on macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha in rheumatoid synovium. J Rheumatol 2001; 28: 2634-2636
60. Ponticelli C, Fogazzi GB. Methylprednisolone pulse therapy for primary glomerulonephritis with nephrotic syndrome. Nephrol Dial Transplant 1989; 6: 381-388
61. Vincent JL. Management of sepsis in the critically ill patient: key aspects. Expert Opin Pharmacother 2006; 7: 2037-2045
62. Raghavan M, Marik PE. Management of sepsis during the early "golden hours". J EmergMed 2006; 2: 185-199
63. Matsumoto Y, Naniwa D, Banno S et al. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher 1998; 2: 300-304
64. Asai T, Nomura S, Ishii K et al. Therapeutic efficacy of leukacytapheresis for procoagulant microparticles during hemophagocytic syndrome. Pathophysiol Haemost Thromb 2008; 36: 98-101
65. Koyama M, Sawada A, YasuiMet al. Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int J Hematol 2007; 86: 466-467
66. Jordan MB, Hildeman D, Kappler J et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+T cells and interferon gamma are essential for the disorder. Blood 2004; 104: 735-743